NICE decision regarding brexucabtagene autoleucel for mantle cell lymphoma
NICE has not recommended the use of brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after two or more lines of systemic treatment.
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
NICE has not recommended the use of brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after two or more lines of systemic treatment.
An opportunity to share your lymphoma experience.
Highlighting the importance of quality health information.
We are here for you every step of the way.
We regularly update our medical information to ensure it is accurate and relevant.
Choose your challenge to support our work and raise lymphoma awareness.
In our latest podcast, Professor David Linch reflects on the changes in lymphoma treatment and support over the past 40 years.
Join us in 2026 for a very special anniversary celebration.
Thank you for your support in 2025.